Trial Profile
Effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Losartan (Primary)
- Indications Hypertension; Metabolic syndrome
- Focus Pharmacodynamics
- 05 Nov 2010 New trial record.